Medical News |
- Long-term rhythm, not rate, control may prolong life with AF
- Emotion perception impaired in patients at risk for psychosis
- Mania symptom profile changes with age
- Evidence tipping against stroke thrombolysis in patients on warfarin
- A third of ED imaging for PE is avoidable
- Cancer experts call for global action on diesel fumes
- Investigational drug slows metastatic breast cancer progression
| Long-term rhythm, not rate, control may prolong life with AF Posted: 14 Jun 2012 05:00 PM PDT Rhythm control therapy for atrial fibrillation may improve survival rates compared with rate control therapy when used long term, show study results published in the Archives of Internal Medicine. |
| Emotion perception impaired in patients at risk for psychosis Posted: 14 Jun 2012 05:00 PM PDT Patients at ultra-high risk for psychosis, as well as those with first-episode schizophrenia, show significant impairments in facial and vocal emotion recognition, researchers report. |
| Mania symptom profile changes with age Posted: 14 Jun 2012 05:00 PM PDT A review of published studies shows that there are significant age-group differences in the prominence of specific symptoms of mania among patients with bipolar disorder. |
| Evidence tipping against stroke thrombolysis in patients on warfarin Posted: 14 Jun 2012 05:00 PM PDT Subtherapeutic warfarin may be harmful in patients undergoing intravenous thrombolysis for stroke, say the authors of a single-center study and meta-analysis. |
| A third of ED imaging for PE is avoidable Posted: 14 Jun 2012 05:00 PM PDT Data from 12 hospitals in the USA indicate that one-third of imaging performed in the emergency department for suspected pulmonary embolism is avoidable, according to a National Quality Forum measure. |
| Cancer experts call for global action on diesel fumes Posted: 13 Jun 2012 05:00 PM PDT Diesel exhaust fumes have been classified as carcinogenic to humans by the International Agency for Research on Cancer, following a week-long meeting of international experts. |
| Investigational drug slows metastatic breast cancer progression Posted: 10 Jun 2012 05:00 PM PDT Trastuzumab emtansine significantly delays disease progression compared with standard therapy in women with human epidermal growth factor receptor-2-positive metastatic breast cancer, show study data presented at the American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, USA. |
| You are subscribed to email updates from MedWire Medical News Combined Feed To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google Inc., 20 West Kinzie, Chicago IL USA 60610 | |
No comments:
Post a Comment